SY
SYRE.US Spyre Therapeutics Inc.
- Market cap
- USD 8.91B
- P/E
- -
- P/B
- 10.42x
- ROE
- -25.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SYRE.US undervalued?
Graham numberThe Graham number of Spyre Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Spyre Therapeutics Inc. fundamental analysis
No fundamental analysis for Spyre Therapeutics Inc. yet.
Spyre Therapeutics Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to…
Full company profileSpyre Therapeutics Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Spyre Therapeutics Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.63M | 5.21M | 3.89M | 0.00 | 0.00 | 18.7M | 2.33M | 886K | 886K | 0.00 | 0.00 |
| Gross Profit | 4.63M | 5.21M | 3.89M | -901K | -1.62M | 18.7M | 2.33M | -78.0K | 886K | -172M | - |
| Operating Income | -21.9M | -27.7M | -45.5M | -80.3M | -81.5M | -65.6M | -84.8M | -242M | -209M | -210M | -257M |
| EBITDA | -21.8M | -27.4M | -45.2M | -77.4M | -79.9M | -64.1M | -82.0M | -242M | -208M | -210M | -277M |
| Net Income | -21.7M | -27.2M | -44.3M | -78.3M | -80.9M | -65.8M | -83.8M | -339M | -208M | -155M | -268M |
| EPS | -55 | -45 | -53 | -61 | -38 | -25 | -25 | -49 | -4.42 | -2.42 | -3.04 |
| Balance Sheet | |||||||||||
| Total Assets | 67.1M | 56.1M | 77.7M | 83.2M | 162M | 110M | 71.1M | 342M | 608M | 778M | 1.10B |
| Total Liabilities | 4.10M | 5.74M | 10.3M | 23.1M | 21.8M | 26.0M | 20.8M | 158M | 90.7M | 62.5M | 48.2M |
| Shareholders' Equity | 63.0M | 50.3M | 67.4M | 60.1M | 140M | 83.9M | 50.3M | 184M | 518M | 715M | 1.05B |
| Cash & Short-term Investments | 63.5M | 50.3M | 74.5M | 71.9M | 146M | 93.1M | 55.7M | 339M | 603M | 757M | 1.07B |
| Total Debt | - | - | - | 5.12M | 5.45M | 5.06M | 4.63M | 84.6M | 84.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -18.8M | -24.6M | -32.2M | -65.7M | -75.8M | -53.7M | -80.1M | -99.9M | -157M | -169M | -273M |
| Capital Expenditure | 212K | 619K | 422K | 1.49M | 4.28M | 573K | 38.0K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -19.1M | -25.2M | -32.6M | -67.2M | -80.1M | -54.3M | -80.2M | -99.9M | -157M | -169M | -273M |
| Ratios | |||||||||||
| ROE | -34.5% | -54.1% | -65.8% | -130.2% | -57.9% | -78.4% | -166.6% | -184.1% | -40.2% | -21.7% | -25.5% |
| ROA | -32.4% | -48.6% | -57.0% | -94.1% | -50.1% | -59.9% | -117.8% | -99.1% | -34.2% | -20.0% | -24.4% |
| Net Profit Margin | -468.8% | -523.3% | -1,140.6% | - | - | -351.1% | -3,598.8% | -38,238.1% | -23,478.3% | - | - |
| Debt to Equity | - | - | - | 0.09x | 0.04x | 0.06x | 0.09x | 0.46x | 0.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Spyre Therapeutics Inc. dividends
Spyre Therapeutics Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Sep 8, 2023.
Who owns Spyre Therapeutics Inc.
- Insiders 1.54%
- Institutions 98.46%
- Public & others 0.00%
- Shares outstanding 95.0M
- Free float 89.0M
Top funds holding SYRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 2.76M | 2.91% | +3.50% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.67M | 2.82% | +7.26% | Sep 2026 |
| American Funds SMALLCAP World A | 2.25M | 2.37% | -12.31% | Sep 2026 |
| iShares Russell 2000 ETF | 1.94M | 2.05% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 1.88M | 1.99% | +103.26% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.82M | 1.93% | +2.68% | Oct 2026 |
| Vanguard MStar Small Cap Value Index | 1.23M | 1.30% | +114.88% | Sep 2026 |
| Polar Capital Biotech S Inc | 935K | 0.99% | 0.00% | Sep 2026 |
| Fidelity Advisor Biotechnology I | 857K | 0.91% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 815K | 0.86% | +0.15% | Aug 2026 |
| Fidelity Growth Company K6 | 805K | 0.85% | +3.33% | Aug 2026 |
| Fidelity Small Cap Growth | 778K | 0.82% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 719K | 0.76% | -0.38% | Oct 2026 |
| Fidelity Series Growth Company | 712K | 0.75% | +2.71% | Aug 2026 |
| Fidelity Select Health Care | 687K | 0.73% | +1.02% | Aug 2026 |
| T. Rowe Price New Horizons | 635K | 0.67% | -7.75% | Sep 2026 |
| T. Rowe Price Health Sciences | 630K | 0.67% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 615K | 0.65% | -0.38% | Oct 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 537K | 0.57% | 0.00% | Sep 2026 |
| Vanguard Explorer Inv | 529K | 0.56% | +110.23% | Sep 2026 |
Top institutions holding SYRE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 13.0M | 13.76% | +10.57% | Jun 2026 |
| BlackRock Inc | 6.51M | 6.87% | +17.85% | Jun 2026 |
| Perceptive Advisors LLC | 4.32M | 4.56% | +14.18% | Jun 2026 |
| RTW INVESTMENTS, LLC | 4.25M | 4.49% | +1.92% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 3.84M | 4.06% | +96.23% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.45M | 3.64% | +12.80% | Jun 2026 |
| State Street Corp | 3.06M | 3.23% | +17.28% | Jun 2026 |
| VR Adviser, LLC | 2.99M | 3.15% | -18.99% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 2.96M | 3.13% | +85.20% | Jun 2026 |
| Driehaus Capital Management LLC | 2.80M | 2.96% | +0.30% | Jun 2026 |
| Geode Capital Management, LLC | 2.56M | 2.71% | +48.89% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.33M | 2.46% | +298.22% | Jun 2026 |
| Capital World Investors | 2.32M | 2.45% | +247.39% | Jun 2026 |
| Jupiter Topco LLC | 2.21M | 2.33% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 1.90M | 2.01% | 0.00% | Jun 2026 |
| TANG CAPITAL MANAGEMENT LLC | 1.89M | 2.00% | 0.00% | Jun 2026 |
| Bank of America Corp | 1.78M | 1.88% | +44.77% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.72M | 1.82% | 0.00% | Jun 2026 |
| Wellington Management Company LLP | 1.58M | 1.67% | -13.33% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.48M | 1.56% | +447.56% | Jun 2026 |
Spyre Therapeutics Inc. company profile
- Company name
- Spyre Therapeutics Inc.
- Ticker
- SYRE.US
- Exchange
- USA Stocks
- Listed since
- Apr 7, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 130
- Fiscal year end
- December
- Address
- Building 23, Waltham, MA, United States, 02453
- Phone
- 617 651 5940
- Website
- spyre.com
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 " anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Spyre Therapeutics Inc. management
10- Dr. Cameron Turtle DPHIL, Ph.D.CEO & Director · born 1990
- Mr. Scott L. BurrowsChief Financial Officer · born 1977
- Ms. Heidy Abreu King-Jones J.D., L.L.M.Chief Legal Officer & Corporate Secretary · born 1983
- Dr. Sheldon Sloan M.B.E., M.D.Chief Medical Officer · born 1959
- Dr. Janet Gunzner-Toste M.B.A., Ph.D.Senior Vice President of Operations
- Mr. Brian ConnollyChief Technical Officer
- Mr. Eric McIntyreSenior Vice President of Finance & Investor Relations
- Mr. James MyersSenior Vice President of Quality & Compliance
- Dr. Justin LaFountaine Ph.D.Senior Vice President of Corporate Development
- Ms. Melissa CooperSenior Vice President of People